Plasma vascular endothelial growth factor and angiogenin are positively related to erythropoietin dose in hemodialysis patients

Eleftheriadis, Theodoros; Antoniadi, Georgia; Liakopoulos, Vassilios; Pissas, Georgios; Galaktidou, Grammati; Stefanidis, Ioannis

doi:10.2478/v10039-012-0071-1

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…noted that serum VEGF is higher in patients with IH, decreasing after 1 month of oral propranolol treatment, while serum VEGF correlates with lesion volume . Meanwhile, the dose of erythropoietin is related to serum VEGF level in adult hemodialysis patients . Therefore, the present patient's reduced serum VEGF observed after treatment may be explained by the cessation of erythropoietin treatment and the suppressive effects of propranolol on VEGF production.…”

Section: Discussionmentioning

confidence: 60%

Diffuse neonatal hemangiomatosis in a very low‐birthweight infant treated with erythropoietin

Okuno

Tokuriki

Yoshino

et al. 2015

Pediatrics International

View full text Add to dashboard Cite

Diffuse neonatal hemangiomatosis (DNH) is a rare condition characterized by the concomitant development of multiple cutaneous infantile hemangiomas (IH) and visceral hemangiomas. Recently, an association between erythropoietin treatment and an increased incidence of infantile hemangioma was noted. A Japanese male infant was born via cesarean section at 27 weeks of gestation. Following the commencement of erythropoietin treatment for anemia of prematurity, he developed multiple cutaneous hemangiomas, high cardiac output heart failure and hepatomegaly. Abdominal imaging indicated comorbidity of diffuse infantile hepatic hemannigomas, resulting in the final diagnosis of DNH. The discontinuation of erythropoietin treatment and long-term therapy with propranolol improved the hepatic lesions and cutaneous hemangiomas. The possibility of multiple organ involvement and the exacerbating effects of erythropoietin treatment should be considered in cases in which multiple cutaneous hemangiomas develop in preterm infants receiving erythropoietin treatment.

show abstract

Section: Discussionmentioning

confidence: 60%